Lv7
4820 积分 2020-03-29 加入
加油加油加油！
Basket trials: From tumour gnostic to tumour agnostic drug development
20小时前
待确认
Tumor-Agnostic Approvals: Insights and Practical Considerations
9天前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
13天前
已完结
Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy
16天前
已完结
Neoadjuvant Chemoimmunotherapy for NSCLC
29天前
已完结
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
29天前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
29天前
已完结
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives
1个月前
已完结
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
1个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
1个月前
已完结
皖公网安备34019202002308
